2003, Clinical Trials, DEA and Events - Medical Cannabis Brief

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2003

Clinical Trials

DEA

Events

AIMS v. Garland: A Disappointment for Psilocybin Advocates, but Progressive Policy May Still be on the Horizon

Cannabis Law Report

FEBRUARY 10, 2022

Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). By Allison Campbell.

DEA

DEA Clinical Trials Policy Research and Development

MAPS Is 36 Years Old – Doblin Provides Precis Timeline of the Organization

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. Later that year, Doblin sued the DEA for the first time. Rick Doblin, Ph.D., and Michael Mithoefer, M.D., Lyle Craker, Ph.D.,

Clinical Trials

Clinical Trials Therapy Research and Development DEA

AIMS v. Garland: A Disappointment for Psilocybin Advocates, but Progressive Policy May Still be on the Horizon

MAPS Is 36 Years Old – Doblin Provides Precis Timeline of the Organization

Stay Connected